Black Rock Inc. Unicycive Therapeutics, Inc. Transaction History

Black Rock Inc.

$4.35 Trillion
Q2 2024

A detailed history of Black Rock Inc. transactions in Unicycive Therapeutics, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 51,837 shares of UNCY stock, worth $223,417. This represents 0.0% of its overall portfolio holdings.

Number of Shares

51,837

Holding current value

$223,417

% of portfolio

0.0%

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$0.4 - $1.46 $20,734 - $75,682	51,837 New	51,837 $25,000
Q2 2022 Aug 12, 2022	SELL	$0.7 - $1.33 $16,916 - $32,140	-24,166 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$1.07 - $2.28 $8,689 - $18,515	8,121 Added 50.61%	24,166 $31,000
Q4 2021 Feb 10, 2022	BUY	$1.81 - $3.05 $8,329 - $14,036	4,602 Added 40.22%	16,045 $33,000
Q3 2021 Nov 09, 2021	BUY	$2.47 - $5.85 $28,264 - $66,941	11,443 New	11,443 $33,000

Others Institutions Holding UNCY

# of Institutions

Shares Held

93.1K

Call Options Held

Put Options Held

View Full List

About Unicycive Therapeutics, Inc.

Ticker UNCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 15,052,500
Market Cap $64.9M
Description
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Al...

More about UNCY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account